AZD2461: A Next-Generation PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC₅₀ of 5 nM, demonstrating cytotoxicity in breast cancer cell lines by inhibiting PARP-1 and inducing cell cycle arrest at the G2 phase (Schwartz 2022). In vivo, AZD2461 reduces PARP activity in murine BRCA1-mutant tumor models for several hours post-administration, with recovery by 24 hours. Its low affinity for P-glycoprotein (Pgp) distinguishes it from earlier PARP inhibitors, enabling activity in resistant tumor settings (Olaparib.net, 2023). AZD2461 is supplied by APExBIO as a solid, is soluble in DMSO and ethanol, and supports experimental concentrations from 5–50 μM for 48–72 h incubations (APExBIO). Long-term administration is well tolerated and prolongs relapse-free survival in animal models.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are nuclear enzymes involved in DNA repair, chromatin remodeling, and regulation of programmed cell death. PARP-1, the most abundant isoform, detects DNA single-strand breaks and facilitates repair via poly-ADP-ribosylation of target proteins (Schwartz 2022). Cancer cells with defects in homologous recombination repair, such as BRCA1/2 mutations, are particularly sensitive to PARP inhibition due to synthetic lethality. Inhibitors like AZD2461 exploit this vulnerability by blocking DNA repair, leading to accumulation of DNA damage and subsequent cell death. Overcoming drug resistance, especially through P-glycoprotein (Pgp) efflux, is a critical challenge in clinical oncology. AZD2461 addresses this limitation by exhibiting reduced Pgp affinity, thereby maintaining efficacy in resistant cancer phenotypes (AZD3514.com, 2023).

Mechanism of Action of AZD2461

AZD2461 selectively inhibits PARP-1 activity, preventing poly-ADP-ribosylation of target proteins involved in DNA repair. In human breast cancer cell lines MCF-7 and SKBR-3, AZD2461 induces concentration- and time-dependent cytotoxicity. Mechanistically, exposure to AZD2461 leads to cell cycle arrest characterized by an increased proportion of cells in the G2 phase and a concomitant reduction in S-phase populations. This G2 arrest results from accumulated DNA damage due to impaired repair mechanisms. In vivo, AZD2461 administration in BRCA1-mutant mouse tumor models effectively suppresses PARP activity for several hours post-dose, with restoration to baseline levels by 24 hours. The compound's low affinity for Pgp efflux pumps distinguishes it from earlier PARP inhibitors, potentially overcoming a key mechanism of acquired chemoresistance (Olaparib.net, 2023).
For a detailed mechanistic and translational perspective, see "AZD2461: Redefining PARP Inhibition for Translational Breast Cancer Research", which this article extends by providing updated benchmarks and workflow integration guidance.

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 activity with an in vitro IC₅₀ of 5 nM under cell-free assay conditions (pH 7.4, 25°C) (APExBIO).
• In MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces viable cell counts in a dose-dependent manner (5–50 μM, 48–72 h incubation) (Schwartz 2022).
• AZD2461 treatment increases the proportion of G2 phase cells and decreases S phase cells, consistent with DNA damage-induced cell cycle arrest (flow cytometry, 48 h, 10 μM) (Schwartz 2022).
• In BRCA1-mutated KB1P tumor-bearing mice, a single dose of AZD2461 (20 mg/kg, i.p.) suppressed tumor PARP activity for up to 6 hours, with PAR levels returning to baseline by 24 hours (Schwartz 2022).
• AZD2461 displays significantly lower affinity for Pgp efflux pumps than olaparib, conferring activity in Pgp-overexpressing tumor models (AZD3514.com, 2023).
• Long-term administration of AZD2461 is well tolerated in mice, with significant prolongation of median relapse-free survival in preclinical tumor models (20 mg/kg, daily, 28 days) (Schwartz 2022).

This article clarifies and extends findings from "AZD2461: Novel PARP Inhibitor for Breast Cancer Research" by providing detailed dosing parameters and benchmarking across multiple cancer models.

Applications, Limits & Misconceptions

AZD2461 is suitable for in vitro and in vivo investigation of DNA repair pathway modulation, synthetic lethality in BRCA1/2-mutant cancers, and studies on overcoming multidrug resistance. The compound's robust activity profile makes it a preferred tool for dissecting PARP signaling in both cell culture and murine models. However, its insolubility in water necessitates the use of DMSO or ethanol (with ultrasonic assistance) for experimental preparations. AZD2461 is not intended for clinical use and should be restricted to research settings.

Common Pitfalls or Misconceptions

• AZD2461 is not effective in cell lines lacking functional PARP-1 or homologous recombination deficiency.
• The compound is insoluble in water; improper solvent selection may compromise experimental integrity.
• Prolonged solution storage reduces compound potency; fresh preparations are recommended for each experiment (store solid at -20°C).
• AZD2461's lower affinity for Pgp does not confer resistance to all forms of drug efflux—other transporters may still limit efficacy.
• Not for clinical or diagnostic applications; strictly for laboratory research use.

Workflow Integration & Parameters

AZD2461 is supplied by APExBIO as a solid with molecular weight 395.43 (C₂₂H₂₂FN₃O₃). For in vitro studies, dissolve in DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL, ultrasonic assistance). Typical working concentrations are 5–50 μM, with incubation periods of 48 to 72 hours. For in vivo murine models, a standard dosing regimen is 20 mg/kg via intraperitoneal injection. Solutions should be freshly prepared and used short-term; store the solid compound at -20°C. For additional troubleshooting and comparative workflow guidance, see "AZD2461: Novel PARP Inhibitor Empowering Breast Cancer Research", which this article updates with new evidence on solvent compatibility and relapse-free survival benchmarks.

Conclusion & Outlook

AZD2461 represents a significant advance in the field of PARP inhibition, combining nanomolar potency with the ability to overcome Pgp-mediated drug resistance. Its robust activity in BRCA1-mutated cancer models and favorable tolerability profile position it as an essential reagent for DNA repair pathway and synthetic lethality research. Ongoing studies will further define its translational impact and expand its utility in combination regimens. For detailed specifications and ordering information, visit the AZD2461 product page at APExBIO.